Current active targeting strategies mainly target growth factor receptors overexpressed in cancers of different tissue origins, such as folate (FA) [166], transferrin (Tf) receptor [167], epidermal growth factor receptor (EGFR) [168,169] and so on [170,171,172]. This evidence concerns the gene EGFR and cancer.